Molbio Diagnostics IPO is a book build issue of — shares (₹- Cr.). The issue is a combination of a fresh issue of — shares (₹200.00 Cr.) and an offer for sale of 91,66,000 shares (₹- Cr.).
The Molbio Diagnostics IPO will open on August 10, 2026, and close on August 12, 2026. The price band for the IPO is fixed at ₹ to ₹ per share. The minimum application size is 1 lot (— shares), requiring a retail investor to invest at least ₹- (based on the upper price band).
Molbio Diagnostics IPO Details
| Open Date | August 10, 2026 |
| Close Date | August 12, 2026 |
| Issue Type | Book Building Issue |
| Face Value | ₹1.00 Equity Share |
| Price Band | ₹ – ₹ Per Share |
| Listing On | BSE, NSE |
| Issue Size | ₹- Cr. (- Shares) |
| Fresh Issue | ₹200.00 Cr. (- Shares) |
| Offer For Sale | ₹- Cr. (91,66,000 Shares) |
| EMP Discount | — |
| Prospectus | RHP |
Molbio Diagnostics IPO Reservation
A total of — shares are on offer in the Molbio Diagnostics IPO, of which — shares have been allotted to QIBs, — shares to NIIs, and — shares to RIIs.
| Category | Reservation | Shares Offered |
|---|---|---|
| QIB | 50.00% | — |
| NII | 15.00% | — |
| RII | 35.00% | — |
| Total | 100.00% | — |
Molbio Diagnostics IPO Market Lot
Retail investors can apply for the Molbio Diagnostics IPO minimum 1 lot of — shares for an application amount of ₹- and a maximum 13 lots of — shares for an amount of ₹-.
| Application | Lot | Shares | Amount |
| Retail Minimum | 1 | ₹ | |
| Retail Maximum | 13 | ₹ | |
| S-HNI Minimum | 14 | ₹ | |
| S-HNI Maximum | 67 | ₹ | |
| B- HNI Minimum | 68 | ₹ |
Key Performance Indicator
| KPI [March 31, 2026] | Value |
| Market Capitalisation | — |
| P/E Ratio | — |
| EPS | ₹14.56 |
| ROE | 15.59% |
| ROCE | 17.55% |
| RoNW | 14.55% |
| Dept/Equity | — |
| EBITDA Margin | 22.56% |
| PAT Margin | 11.28% |
| Net Assets Value | ₹101.51 |
| Price To Book Value | — |
Molbio Diagnostics IPO Peer Comparison
| Company | P/E | EPS | RoNW | NAV |
| Poly Medicure Limited | 52.61x | ₹31.79 | 10.37% | ₹306.45 |
| Dr. Lal Pathlabs Limited | 62.20x | ₹30.24 | 20.78% | ₹145.00 |
| Metropolis Healthcare Limited | 63.72x | ₹9.19 | 12.56% | ₹72.98 |
| Vijaya Diagnostic Centre Limited | 81.02x | ₹16.81 | 18.07% | ₹93.02 |
Molbio Diagnostics IPO Dates
Molbio Diagnostics IPO open for subscription August 10, 2026, and close date on August 12, 2026. The allotment will be finalized on August 13, 2026, and the IPO listing on August 17, 2026.
| Open Date | August 10, 2026 |
| Close Date | August 12, 2026 |
| Allotment Date | August 13, 2026 |
| Refund Date | August 14, 2026 |
| Share Credit Date | August 14, 2026 |
| Listing Date | August 17, 2026 |
Molbio Diagnostics Limited Company Financial Report
| Period Ended | Total Assets | Total Income | Total Expenses | Net Worth | Profit After Tax | EBITDA | Reserves and Surplus | Total Borrow |
|---|---|---|---|---|---|---|---|---|
| March 2026 | ₹2,148.42 Cr. | ₹1,455.17 Cr. | ₹ Cr. | ₹1,144.68 Cr. | ₹164.14 Cr. | ₹328.24 Cr. | ₹1,148.84 Cr. | ₹412.64 Cr. |
| March 2025 | ₹1,461.56 Cr. | ₹1,027.94 Cr. | ₹ Cr. | ₹952.95 Cr. | ₹138.58 Cr. | ₹256.64 Cr. | ₹990.84 Cr. | ₹123.16 Cr. |
| March 2024 | ₹1,221.06 Cr. | ₹840.66 Cr. | ₹ Cr. | ₹807.94 Cr. | ₹83.54 Cr. | ₹185.09 Cr. | ₹845.48 Cr. | ₹174.58 Cr. |
Company Promoters
- Chandrasekhar Bhaskaran Nair
- Exxora Trading LLP
- Sangeetha Sriram
- Shiva Sriram
- Sowmya Sriram
- Sriram Natarajan
| Holding Pre Issue | 46.65% |
| Holding Post Issue | — |
Molbio Diagnostics IPO Lead Managers
- Kotak Mahindra Capital Company Limited
- IIFL Capital Services Limited
- Jefferies India Private Limited
- Motilal Oswal Investment Advisors Limited
Molbio Diagnostics IPO Registrar
Kfin Technologies Limited
Phone: 040-79615565
Email: molbio.ipo@kfintech.com
Website: https://ipostatus.kfintech.com/
About Molbio Diagnostics Limited
Incorporated in October 2000, Molbio Diagnostics Limited is a global point-of-care molecular diagnostics company specializing in the research, development, manufacturing, and commercialization of rapid diagnostic solutions. The firm is best known for its proprietary “TrueNat” platform, a portable, battery-powered, PCR-based molecular diagnostic system specifically designed for use in resource-poor settings. Capable of delivering accurate, lab-quality test results within an hour, the WHO-endorsed TrueNat platform supports diagnostic assays for over 30 diseases, including serious public health conditions such as tuberculosis, COVID-19, HIV, hepatitis B and C, and HPV. In addition to core molecular diagnostics, the company has expanded its clinical ecosystem to cover radiology, digital pathology, and breast health screening through strategic subsidiaries and ongoing research initiatives.
The company operates a scalable business model based on a regular revenue stream from its proprietary diagnostic test kits and consumable assays. Its operational footprint includes six manufacturing facilities across India, supporting a global distribution network spanning over 90 countries. Its client base includes government health programs, diagnostic labs, private hospitals, and international healthcare organizations. Backed by a large global patent portfolio, international regulatory certifications, and strategic acquisitions, the company is expanding its product pipeline and strengthening its position as a leading innovator in the healthcare diagnostics sector.
Led by an experienced management team with deep technical expertise in healthcare innovation, Molbio Diagnostics balances internal research and development strengths with active strategic partnerships. This balanced approach allows the company to consistently deliver seamless, high-precision healthcare solutions to markets worldwide. To manage its global manufacturing, clinical testing, regulatory compliance, R&D programs, and commercial operations, the company has established a dedicated workforce of 1,225 permanent employees across its various business divisions through March 31, 2026.
Objects Of The Issue
- Funding capital expenditure towards the setting up of infrastructure for research and development facility, Center of Excellence and connected office space. (Estimated Ammount ₹125.12 Cr.)
- Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit (Estimated Ammount ₹125.12 Cr.)
- General Corporate Purposes
Company Address
Molbio Diagnostics Limited
Address: Plot No. L-46
Phase II-D, Verna Industrial Area
Verna, Salcete
South Goa, Goa, 403722
Phone: 8326724888
Email: investors@molbiodiagnostics.com
Website: https://www.molbiodiagnostics.com/
Molbio Diagnostics IPO FAQs
What is Molbio Diagnostics IPO?
Molbio Diagnostics IPO is a MainBoard IPO of — equity shares of the face value of ₹1 aggregating up to ₹- Cr. The IPO issue priced at ₹ to ₹ per share.
What are the open and close dates of the Molbio Diagnostics IPO?
The IPO will open on August 10, 2026 and will close on August 12, 2026.
What is the price band for Molbio Diagnostics IPO?
The price band for the IPO is fixed at ₹ to ₹ per share.
What is the issue size of the Molbio Diagnostics IPO?
The total issue size of the IPO is ₹- Cr., comprising both fresh issue and offer for sale (if applicable).
What is Molbio Diagnostics IPO Minimum and Maximum Lot Size?
The minimum bid is 1 Lot, — Shares with ₹- amount while the maximum bid is 13 Lot, — shares with ₹- for the IPO.
What is Molbio Diagnostics IPO Investors Portion?
The investors’ portion for QIB 50%, NII 15%, RII 35% for the IPO.
When will the basis of allotment for the Molbio Diagnostics IPO be finalized?
The the IPO allotment is expected to be finalized on August 13, 2026.
When will the shares of Molbio Diagnostics IPO get listed?
The IPO shares are expected to be listed on the BSE and NSE on August 17, 2026.
This content has been researched and written by the IPO Investors Team…
Disclaimer: Readers are strongly advised to seek guidance from a qualified financial advisor before making any investment decisions. Relying solely on the content presented here for financial choices is done entirely at the reader’s own risk.
| Thank You… |
|---|